The introduction of BTK inhibitors has transformed the treatment landscape for CLL, MCL, and WM, offering patients a more effective and tolerable alternative to traditional therapies. By specifically targeting cancer cells and minimising damage to healthy ones, these treatments have provided new hope for many battling blood cancers.
